First Time Loading...

ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 4.49 USD 6.9%
Updated: Mar 29, 2024

Relative Value

The Relative Value of one ADCT stock under the Base Case scenario is 5.51 USD. Compared to the current market price of 4.49 USD, ADC Therapeutics SA is Undervalued by 19%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ADCT Relative Value
Base Case
5.51 USD
Undervaluation 19%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
35
vs Industry
63
Median 3Y
2.2
Median 5Y
1.6
Industry
8.2
Forward
4.5
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-4.1
Industry
26
Forward
-2.4
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-3.7
Industry
21.5
vs History
vs Industry
Median 3Y
-2.4
Median 5Y
-3.5
Industry
24.3
vs History
vs Industry
52
Median 3Y
4.7
Median 5Y
5.6
Industry
2.7
vs History
27
vs Industry
45
Median 3Y
2
Median 5Y
1.5
Industry
7.4
Forward
6.3
vs History
25
vs Industry
48
Median 3Y
2.1
Median 5Y
1.5
Industry
9.4
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-3.5
Industry
4.2
Forward
-4
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-3.4
Industry
4.3
Forward
-3.5
vs History
vs Industry
Median 3Y
-3.1
Median 5Y
-3.9
Industry
5.3
vs History
vs Industry
Median 3Y
-3.1
Median 5Y
-3.8
Industry
3.3
vs History
43
vs Industry
25
Median 3Y
4.7
Median 5Y
7.8
Industry
5

Multiples Across Competitors

ADCT Competitors Multiples
ADC Therapeutics SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
ADC Therapeutics SA
NYSE:ADCT
370.6m USD 5.3 -1.5 -3.2 -3.1
US
Abbvie Inc
NYSE:ABBV
321.6B USD 5.9 66.7 14.3 21.8
US
Amgen Inc
NASDAQ:AMGN
152.2B USD 5.4 22.7 16.7 25
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
107.7B USD 10.9 29.8 23.9 25.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
105.3B USD 8 26.6 18 19.8
US
Gilead Sciences Inc
NASDAQ:GILD
91.3B USD 3.4 16.1 9.6 12.8
AU
CSL Ltd
ASX:CSL
139.1B AUD 6.4 36.7 22.1 27.4
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Moderna Inc
NASDAQ:MRNA
40.7B USD 5.9 -8.6 -9 -7.7
US
Biogen Inc
NASDAQ:BIIB
31.2B USD 3.2 26.9 14.5 18
KR
Celltrion Inc
KRX:068270
41.5T KRW 18 68.8 43.2 56.7
P/E Multiple
Earnings Growth
CH
ADC Therapeutics SA
NYSE:ADCT
Average P/E: 36.8
Negative Multiple: -1.5
N/A
US
Abbvie Inc
NYSE:ABBV
66.7
403%
US
Amgen Inc
NASDAQ:AMGN
22.7
79%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.8
49%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
26.6
44%
US
Gilead Sciences Inc
NASDAQ:GILD
16.1
74%
AU
CSL Ltd
ASX:CSL
36.7
83%
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -57.5 N/A
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -8.6 N/A
US
Biogen Inc
NASDAQ:BIIB
26.9
152%
KR
Celltrion Inc
KRX:068270
68.8
105%
EV/EBITDA Multiple
EBITDA Growth
CH
ADC Therapeutics SA
NYSE:ADCT
Average EV/EBITDA: 20.3
Negative Multiple: -3.2
N/A
US
Abbvie Inc
NYSE:ABBV
14.3
25%
US
Amgen Inc
NASDAQ:AMGN
16.7
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
59%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
51%
US
Gilead Sciences Inc
NASDAQ:GILD
9.6
29%
AU
CSL Ltd
ASX:CSL
22.1
54%
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -61.9 N/A
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -9 N/A
US
Biogen Inc
NASDAQ:BIIB
14.5
71%
KR
Celltrion Inc
KRX:068270
43.2
68%
EV/EBIT Multiple
EBIT Growth
CH
ADC Therapeutics SA
NYSE:ADCT
Average EV/EBIT: 25.8
Negative Multiple: -3.1
N/A
US
Abbvie Inc
NYSE:ABBV
21.8
81%
US
Amgen Inc
NASDAQ:AMGN
25
101%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.1
61%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.8
51%
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
54%
AU
CSL Ltd
ASX:CSL
27.4
70%
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -55.8 N/A
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -7.7 N/A
US
Biogen Inc
NASDAQ:BIIB
18
76%
KR
Celltrion Inc
KRX:068270
56.7
89%

See Also

Discover More